Pharma exports to overtake domestic sales in FY15: Ind Ratings

India Ratings & Research has revised its outlook on the pharmaceuticals sector for next fiscal to positive from stable on the back of increased exports.

The domestic pharmaceutical market is likely to see high single-digit revenue growth. Profit margins are likely to improve on improved utilisation of manufacturing facilities, the rating agency said in its '2014 Outlook: Pharmaceuticals' report here.

The outlook for most Ind-Ra rated pharmaceutical companies is stable as almost all of the positive factors have already been factored into the existing ratings.

Ind-Ra expects the credit profiles of these companies to continue to strengthen in FY15 on the back of increasing revenue and improving margins on increased exports, it said.

Ind-Ra believes the strong export growth recorded over 2007-08 - 2012-13 (CAGR of 22%) will continue in the medium term.

This growth will be backed by $92 billion of drugs going off patent in the next three years, increasing traction for generic drugs globally and new generic drug approvals for Indian pharmaceutical companies in different jurisdictions.

However, the domestic market revenue growth (CAGR of 10.4% over FY08-FY13) will continue to be moderate.

The rating agency said exports to the US will continue to grow in the medium term backed by the largest number of United States Food & Drug Administration (USFDA) approved facilities outside the US as well as the largest share of drug approvals over the last few years.

Approvals from the World Health Organisation and European regulators are also strong providing added visibility for exports. Although 2013 saw high regulatory actions against Indian pharmaceutical manufacturers, Ind-Ra believes they do not weaken the industry's prospects.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • The NDA government would do well to keep its economic focus in place

    It is as if the worst horrors conjured by liberal secularists about India’s prime minister could be finally coming true.

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Urs Schöttli

Shifting sands in the Far East

As was to be expected, Japanese prime minister Shinzo Abe ...

Zehra Naqvi

When humanity died, bestiality prevailed

The terrorist attack that killed 132 children in Peshawar has ...

Bubbles Sabharwal

Why self-esteem must be your best friend forever

Two negatives do make a positive! Imagine no doubts, no ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture